Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217667 · ClinicalTrials.gov registry record · Phase 2
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
A Phase 2 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT05217667: Active Phase 2 study of Homozygous Familial Hypercholesterolemia, sponsored by Arrowhead Pharmaceuticals.
NCT05217667 is a Phase 2 study of Homozygous Familial Hypercholesterolemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 18 participants, below the 249-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05217667, a Phase 2 study of Homozygous Familial Hypercholesterolemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to continue in an additional 24-month extension period during which they will receive up to 8 doses open-label doses of ARO-ANG3.
Primary Outcome
LDL-C, computed using Friedewald formula, Martin-Hopkins methodology and preparative ultracentrifugation (PUC).
Conditions Studied
Interventions
- DRUG ARO-ANG 3 Injection
Study Locations (7)
Quebec
- Research Site 2 - Chicoutimi
- Research Site 1 - Québec
New York
- Research Site 4 - Mount Sinai
Ohio
- Research Site 5 - Cincinnati
New South Wales
- Research Site 8 - Camperdown
Western Australia
- Research Site 3 - Nedlands
Other
- Research Site 7 - Johannesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-11 |
| Phase | Phase 2 |
What the registry record for NCT05217667 still lists
NCT05217667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 249-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which ARO-ANG 3 Injection is the first listed.
NCT05217667 lists 7 locations in 6 states (Quebec, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT05217667 about?
NCT05217667 is a clinical study titled "Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)". Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to co...
What is the current status of trial NCT05217667?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-04-22. Estimated completion is 2025-11.
What conditions does trial NCT05217667 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.
What interventions are being tested in trial NCT05217667?
The interventions under investigation include: ARO-ANG 3 Injection (DRUG).
Who is sponsoring clinical trial NCT05217667?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217667 being conducted?
This trial has 7 study locations across New York, Ohio, New South Wales, Western Australia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
COMPLETED · Phase 2
-
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
RECRUITING
-
HoFH, the International Clinical Collaborators Registry
RECRUITING
-
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
RECRUITING · Phase 3
-
LOWER: Lomitapide Observational Worldwide Evaluation Registry
RECRUITING
-
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI